文献速递乳腺癌消化系统肿瘤

Trastuzumab deruxtecan(DS-8201)在晚期乳腺癌及胃或胃食管肿瘤中的安全性、药代动力学和抗肿瘤活性:一项1期剂量递增研究

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
PubMed 文献 · Lancet Oncol · 2017-10-13

未达到最大耐受剂量,未观察到剂量限制性毒性;

要点

  • 未达到最大耐受剂量,未观察到剂量限制性毒性、明显心血管毒性或死亡。
  • 23例可评估患者客观缓解率43%,疾病控制率91%。

核心结论

  • 未达到trastuzumab deruxtecan的最大耐受剂量。
  • 在该样本量小、经重度既往治疗的人群中,trastuzumab deruxtecan显示出抗肿瘤活性,即使在低HER2表达肿瘤中亦如此。

研究设计与样本

  • 开放标签、剂量递增1期试验,在日本两个研究中心开展。
  • 纳入至少20岁、标准治疗难治的乳腺癌或胃/胃食管癌患者,无论HER2状态。
  • 主要终点为安全性和最大耐受剂量或2期推荐剂量的确定,在所有至少接受一剂研究药物的参与者中分析。

主要发现

  • 截至2017年2月1日研究截止日期,未发生剂量限制性毒性、明显心血管毒性或死亡。
  • 最常见的3级不良事件为淋巴细胞减少(3例)和中性粒细胞减少(2例);1例患者报告4级贫血。
  • 3例严重不良事件——发热性中性粒细胞减少、肠穿孔和胆管炎——各由1例患者报告。

临床怎么用

  • 对于标准治疗难治的晚期乳腺癌或胃/胃食管癌患者,trastuzumab deruxtecan在1期研究中显示出抗肿瘤活性,包括低HER2表达肿瘤。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antibody-drug conjugates have emerged as a powerful strategy in cancer therapy and combine the ability of monoclonal antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. Trastuzumab deruxtecan (also known as DS-8201) is an antibody-drug conjugate comprised of a humanised antibody against HER2, a novel enzyme-cleavable linker, and a topoisomerase I inhibitor payload. We assessed its safety and tolerability in patients with advanced breast and gastric or gastro-oesophageal tumours. METHODS: This was an open-label, dose-escalation phase 1 trial done at two study sites in Japan. Eligible patients were at least 20 years old with breast or gastric or gastro-oesophageal carcinomas refractory to standard therapy regardless of HER2 status. Participants received initial intravenous doses of trastuzumab deruxtecan from 0·8 to 8·0 mg/kg and dose-limiting toxicities were assessed over a 21-day cycle; thereafter, dose reductions were implemented as needed and patients were treated once every 3 weeks until they had unacceptable toxic effects or their disease progressed. Primary endpoints included identification of safety and the maximum tolerated dose or recommended phase 2 dosing and were analysed in all participants who received at least one dose of study drug. The dose-escalation study is the first part of a two-part study with the second dose-expansion part ongoing and enrolling patients as of July 8, 2017, in Japan and the USA. This trial is registered at ClinicalTrials.gov, number NCT02564900. FINDINGS: Between Aug 28, 2015, and Aug 26, 2016, 24 patients were enrolled and received trastuzumab deruxtecan (n=3 for each of 0·8, 1·6, 3·2, and 8·0 mg/kg doses; n=6 for each of 5·4 and 6·4 mg/kg). Up to the study cutoff date of Feb 1, 2017, no dose-limiting toxic effects, substantial cardiovascular toxic effects, or deaths occurred. One patient was removed from the activity analysis because they had insufficient target lesions for analysis. The most common grade 3 adverse events were decreased lymphocyte (n=3) and decreased neutrophil count (n=2); and grade 4 anaemia was reported by one patient. Three serious adverse events-febrile neutropenia, intestinal perforation, and cholangitis-were reported by one patient each. Overall, in 23 evaluable patients, including six patients with low HER2-expressing tumours, ten patients achieved an objective response (43%, 95% CI 23·2-65·5). Disease control was achieved in 21 (91%; 95% CI 72·0-98·9) of 23 patients. Median follow-up time was 6·7 months (IQR 4·4-10·2), with nine (90%) of ten responses seen at doses of 5·4 mg/kg or greater. INTERPRETATION: The maximum tolerated dose of trastuzumab deruxtecan was not reached. In this small, heavily pretreated study population, trastuzumab deruxtecan showed antitumour activity, even in low HER2-expressing tumours. Based on safety and activity, the most likely recommended phase 2 dosing is 5·4 or 6·4 mg/kg. FUNDING: Daiichi Sankyo Co, Ltd.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Doi T, Shitara K, Naito Y, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017. PMID: 29037983. doi:10.1016/S1470-2045(17)30604-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。